1. Home
  2. NEXT vs PHVS Comparison

NEXT vs PHVS Comparison

Compare NEXT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextDecade Corporation

NEXT

NextDecade Corporation

HOLD

Current Price

$5.02

Market Cap

1.6B

Sector

Energy

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$24.98

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXT
PHVS
Founded
2010
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NEXT
PHVS
Price
$5.02
$24.98
Analyst Decision
Hold
Buy
Analyst Count
2
9
Target Price
$9.00
$39.44
AVG Volume (30 Days)
3.6M
271.8K
Earning Date
02-27-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.99
$11.51
52 Week High
$12.12
$29.80

Technical Indicators

Market Signals
Indicator
NEXT
PHVS
Relative Strength Index (RSI) 34.71 48.84
Support Level $5.23 $23.62
Resistance Level $5.47 $28.43
Average True Range (ATR) 0.21 1.57
MACD -0.01 -0.15
Stochastic Oscillator 29.01 29.52

Price Performance

Historical Comparison
NEXT
PHVS

About NEXT NextDecade Corporation

NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas and sale of LNG and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: